Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years - Novartis ( NYSE:NVS )
Novartis AG NVS released new data Wednesday from the ALITHIOS open-label extension study.
| Ticker |
Sentiment |
Impact |
|
NVS
|
Neutral
|
22 %
|
|
SNY
|
Neutral
|
22 %
|
